Related Experiment Video

Updated: Oct 12, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Oncogenic KRAS: Signaling and Drug Resistance

Hyeon Jin Kim1, Han Na Lee1, Mi Suk Jeong2

  • 1Department of Molecular Biology, College of Natural Sciences, Pusan National University, Jangjeon-dong, Geumjeong-gu, Busan 46241, Korea.

Cancers
|November 27, 2021
PubMed

Insights

RAS proteins regulate cell signaling, but KRAS mutations drive cancer. This review explores KRAS biology and targeted cancer therapies, offering new insights for treatment strategies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • RAS proteins are crucial for cell signaling pathways, controlling growth, division, and survival.
  • RAS proteins function as GTPase switches, cycling between inactive GDP-bound and active GTP-bound states.
  • KRAS, a RAS superfamily member, is frequently mutated in various human cancers, driving oncogenesis.

Purpose of the Study:

  • To review the biological characteristics of RAS proteins, particularly KRAS.
  • To summarize recent advancements in developing KRAS-targeted anticancer therapies.
  • To provide new insights into KRAS-mutant cancer treatment.

Main Methods:

  • Literature review of biological characteristics of RAS proteins.
  • Analysis of recent research on KRAS-targeted anticancer strategies.
  • Synthesis of current knowledge on KRAS mutations in cancer.

Main Results:

  • KRAS mutations are key drivers of cancer development and progression.
  • Targeting mutated KRAS remains a significant challenge in oncology.
  • Recent therapeutic strategies show promise in overcoming KRAS-driven oncogenesis.

Conclusions:

  • Understanding KRAS biology is essential for effective cancer therapy.
  • Continued research into KRAS-targeted treatments is critical for improving patient outcomes.
  • This review highlights progress and future directions in targeting KRAS in cancer.
Keywords:
GTPaseKRASdrug resistanceinhibitormutantsignaling

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K